Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On Thursday, Moderna Inc. MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion.

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Vertex Pharmaceuticals

Both stocks have made significant breakthroughs.

2 Biotech Stocks You Can Buy Hand Over Fist This Month

Moderna has received approval from Canada's health regulator for its respiratory syncytial virus vaccine in adults 60 years of age and older, the vaccine maker said on Friday.

Canada approves Moderna's RSV vaccine for adults aged 60 and older

Carisma Therapeutics Inc

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully create CAR-M directly in vivo, reprogramming endogenous myeloid cells to target and destroy Glypican-3 ("GPC3"), expressing cancer cells.

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.1 "Today's approval is an example of how our mRNA platform can help address significant public health challenges like RSV," said Stéphane Bancel, Chief Executive Officer of Moderna. "As our second product approved by Health Canada, mRESVIA underscores our commitment to leveraging mRNA technology to protect vulnerable populations and contribute to a healthier future for Canadians.

Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.

Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View

Moderna (MRNA) reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs.

Moderna Stock Rises on Surprise Q3 Profit

Call Start: 08:00 January 1, 0000 9:00 AM ET Moderna Inc. (NASDAQ:MRNA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 am ET Company Participants Stéphane Bancel - Chief Executive Officer Stephen Hoge - President Jamey Mock - Chief Financial Officer Lavina Talukdar - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Eli Merle - UBS Gena Wang - Barclays Michael Yee - Jefferies Tyler Van Buren - TD Cowen Terence Flynn - Morgan Stanley Evan Wang - Guggenheim Edward Tenthoff - Piper Sandler Luca Issi - RBC Capital Courtney Breen - Bernstein Manos Mastorakis - Deutsche Bank Operator Good day and thank you for standing by. Welcome to the Moderna third quarter 2024 conference call.

Moderna (MRNA) Q3 2024 Earnings Call Transcript

Planet Fitness

Under Armour

The other long-expected big news item for market participants this week comes this afternoon, with the Federal Open Market Committee (FOMC) determining a new Fed funds rate. This follows the “red wave” election on Tuesday that still shows stock market indexes going higher after a gangbusters market Wednesday.

Initial Claims Increased Slightly More Than Expected

The long-expected big news item for market participants this afternoon is the Fed interest rate move.

Ahead of Fed Decision, Big Earnings Wins for Forgotten Names

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of its COVID-19 vaccine, despite lower-than-anticipated revenue from its new respiratory syncytial virus (RSV) vaccine. Shares of the Cambridge, Massachusetts-based company jumped 11% in premarket trading.

Moderna posts surprise profit as COVID vaccine sales exceed expectations

The stock price of Moderna has seen a sharp 48% fall this year. From its lows of around $50, it is expected to see a rebound after posting a solid Q3 beat.

Buy, Sell, Or Hold MRNA Stock?

On Thursday, Moderna Inc  MRNA stock is trading higher after the company reported better-than-expected third-quarter sales.

Moderna Q3 Revenue Beats On Updated COVID-19 Vaccine, Slashes Expenses For 2024

Moderna (MRNA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $1.89 per share. This compares to loss of $1.39 per share a year ago.

Moderna (MRNA) Q3 Earnings and Revenues Surpass Estimates

Moderna Inc.'s stock jumped 5% early Thursday, after the company's third-quarter earnings showed an unexpected profit and revenue that beat estimates by a wide margin.

Moderna's stock pops after biotech ekes out profit and revenue beats by a wide margin

Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected.  Moderna said Thursday its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.

Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.

Moderna reports surprise profit on higher-than-expected COVID vaccine sales

Moderna crushed third-quarter views on Thursday and turned around a surprise profit, but Moderna stock could slump on light RSV vaccine sales. The post Moderna Posts A Surprise Profit As Sales Wallop Views.

Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billion Initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenza Announces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024. "During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe.

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.

Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Dollar Tree

Estee Lauder

Intel

Walgreens

Perhaps this list is a good place to start bargain-hunting.

These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over

ASML Hld

IDEXX Laboratories

Regeneron Pharmaceuticals

Super Micro Computer

Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Gilead Sciences

Novo Nordisk

Teva Pharmaceutical

Viatris

Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg Law reported on Tuesday citing one person familiar with the matter.

News for Moderna Stock (MRNA)